Medical Marijuana Legalization in Oklahoma: Effects on Neonatal Exposure to Opiates
American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e1069-e1074
DOI: 10.1055/a-1990-8311 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Lise DeShea und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Neonatal-Perinatal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. Hauptthemen laut MEDLINE: Medical Marijuana. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Objective
The U.S. opioid epidemic has been characterized by increases in opioid misuse, overdose deaths, and neonatal opioid withdrawal syndrome. Research suggests that marijuana legalization has contributed to decreased use of opiates, although many studies had methodological weaknesses and failed to address the pregnant population. Implementation of medical cannabis laws has the potential to reduce maternal opioid use and, therefore, neonatal exposure to the drugs. This study aimed to examine the association between Oklahoma's implementation of state medical marijuana laws and the neonatal exposure to opioids. Study Design Electronic medical records at two sites (Oklahoma City and Lawton) were searched for results of cord, urine, and meconium screens to detect amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, opiates, phencyclidine, and tetrahydrocannabinol (THC). Two study periods were compared: 19 months before Oklahoma's medical marijuana law took effect and 19 months after legalization began.
Results
A total of 16,804 babies were born alive at the two sites during the study period. The rate of positive THC tests per 1,000 liveborn infants significantly increased from 16.2 per 1,000 during the prelaw period to 22.2 per 1,000 during the postlaw period (p = 0.004). Neonatal opioid exposure incidence showed a nonsignificant decrease from 7.6 positive tests per 1,000 liveborn infants to 6.8 per 1,000 from prelaw to postlaw period (p = 0.542). The number of positive tests for THC and concomitant use of opioids doubled from the prelaw period (n = 4) to postlaw (n = 9), but there were too few cases for statistical significance. Infants at the more rural site had significantly higher rates for amphetamines, benzodiazepines, and THC, with a trend toward higher rates for opiates.
Conclusion
Marijuana legalization was related to significant increases in positive test rates for THC, but no significant change/association was noted for neonatal exposure to opioids. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Neonatal-Perinatal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
- University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.
- OU Health, Comanche County Memorial Hospital, Neonatal Intensive Care Unit, Lawton, Oklahoma.
- Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Förderung
- NIGMS NIH HHS
Zitieren
APA
DeShea, L., Rolfs, S., McCoy, M., Beasley, W. H., Szyld, E., & Makkar, A. (2024). Medical Marijuana Legalization in Oklahoma: Effects on Neonatal Exposure to Opiates. American Journal of Perinatology, 41(S 01 S 01), e1069-e1074. https://doi.org/10.1055/a-1990-8311
Vancouver
DeShea L, Rolfs S, McCoy M, Beasley WH, Szyld E, Makkar A. Medical Marijuana Legalization in Oklahoma: Effects on Neonatal Exposure to Opiates. American Journal of Perinatology. 2024;41(S 01 S 01):e1069-e1074. doi:10.1055/a-1990-8311
BibTeX
@article{DeShea2024,
author = {DeShea, Lise and Rolfs, Shanna and McCoy, Mike and Beasley, William H and Szyld, Edgardo and Makkar, Abhishek},
title = {Medical Marijuana Legalization in Oklahoma: Effects on Neonatal Exposure to Opiates},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {S 01 S 01},
pages = {e1069--e1074},
doi = {10.1055/a-1990-8311}
}
EUVIMED